SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
about
The effect of SGLT2 inhibitors on cardiovascular events and renal function.Relationship between cardiac microvascular dysfunction measured with 82Rubidium-PET and albuminuria in patients with diabetes mellitus.Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy.Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease
P2860
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
@ast
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
@en
type
label
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
@ast
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
@en
prefLabel
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
@ast
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
@en
P2093
P2860
P921
P1476
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
@en
P2093
Baoqin Zhou
Honghong Zou
P2860
P2888
P356
10.1186/S12933-017-0547-1
P407
P577
2017-05-16T00:00:00Z
P6179
1085379613